Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells

Molecular Cancer Therapeutics

Volumn 5, Issue 3, 2006, Pages 502-508

  Arakawa, Yasuhiro ^a   Suzuki, Hideaki ^a   Saito, Shinobu ^a   Yamada, Hisashi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; GLYCINE; MITOMYCIN C; SERINE; TOPOTECAN;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CATALYSIS; CELL NUCLEUS; COLON CANCER; COMPLEX FORMATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DNA INTERACTION; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME STABILITY; GENE LOSS; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; GLYCINE; HUMANS; MUTATION, MISSENSE; PROTEIN CONFORMATION; SERINE;

EID: 33645464043     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0246     Document Type: Article

References (28)

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
2. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
4. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
5. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
6. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003;22:7296-304.
7. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998;279:1504-13.
8. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ. A model for the mechanism of human topoisomerase I. Science 1998;279:1534-41.
9. Laco GS, Collins JR, Luke BT, et al. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry 2002;41:1428-35.
10. Chrencik JE, Staker BL, Burgin AB, et al. Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol 2004; 339:773-84.
11. Chang JY, Dethlefsen LA, Barley LR, Zhou BS, Cheng YC. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 1992;43:2443-52.
12. Urasaki Y, Laco GS, Pourquier P, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 2001;61:1964-9.
13. Bonven BJ, Gocke E, Westergaard O. A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin. Cell 1985;41:541-51.
14. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky EK. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 1997;89:2098-104.
15. Eng WK, McCabe FL, Tan KB, et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 1990;38:471-80.
16. Kanzawa F, Sugimoto Y, Minato K, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1990;50:5919-24.
17. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990;50: 6925-30.
18. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 1995;55:1339-46.
19. Chang JY, Liu JF, Juang SH, Liu TW, Chen LT. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res 2002;62:3716-21.
20. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995;270:21429-32.
21. Ellis AL, Nowak B, Plunkett W, Zwelling LA. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother Pharmacol 1994;34:249-56.
22. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002;277:26553-64.
23. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991;51:6039-44.
24. Chen ZS, Furukawa T, Sumizawa T, et al. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999;55:921-8.
25. Li XG, Haluska P, Jr., Hsiang YH, et al. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Biochem Pharmacol 1997;53:1019-27.
26. Wheeler JM, Beck NE, Kim HC, Tomlinson IP, Mortensen NJ, Bodmer WF. Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: the predominant role of hMLH1. Proc Natl Acad Sci U S A 1999;96:10296-301.
27. Gradia S, Acharya S, Fishel R. The human mismatch recognition complex hMSH2-6 functions as a novel molecular switch. Cell 1997; 91:995-1005.
28. Tsurutani J, Nitta T, Hirashima T, et al. Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer 2002;35:299-304.